In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing
Molecular Therapy Advances · 2026-09 · 34 (3) · 201816
DOI: 10.1016/j.omta.2026.201816 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-09. Verfasst von Asma Naseem und 14 weiteren Autor:innen. Beteiligte Einrichtung: Infection, Immunity & Inflammation Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, University College London, 20…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI Medical Research Council, Ministero dell'Istruzione dell'Università e della Ricerca, Great Ormond Street Hospital Children's Charity.
Abstract (Originalsprache)
Translating CRISPR-Cas9-based homology-directed repair (HDR) strategies into clinical application remains a major challenge due to limited standardization, concerns over safety, and efficacy issues. Here, we present a comprehensive and clinically compliant preclinical framework for the ex vivo correction of Wiskott-Aldrich syndrome (WAS) using a CRISPR-Cas9-AAV6 platform targeting hematopoietic stem and progenitor cells (HSPCs). In this study, we established a clinical-compatible platform enabling large-scale manufacturing while preserving HSPC viability, stemness, and multilineage functionality. To overcome low HSPC long-term engraftment, we fine-tuned AAV dosing and transiently modulated p53BP-dependent DNA damage response pathway, achieving significantly improved in vivo correction and repopulation. Importantly, we implemented a multi-tiered genotoxicity assessment strategy, integrating in silico, genome-wide, and orthogonal assays, revealing a largely favorable safety profile with minimal off-target risks and no evidence of clonal dominance or transformation during the study period. Longitudinal in vivo safety monitoring revealed donor-specific rare off-target events and structural variants. This highlights the crucial importance of patient monitoring after transplantation, further emphasized by the identification of a de novo chromosomal rearrangement that could be detected exclusively following cell engraftment in mice. This work offers a robust and adaptable roadmap for future HDR-based gene editing platforms, establishing critical benchmarks for efficacy, safety, and regulatory readiness in the development of advanced therapeutic medicinal products.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Infection, Immunity & Inflammation Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, University College London, 20 Guilford Street, London WC1N 1DZ, UK.
- Center for Genomic Medicine and Rare Diseases, Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
- Division of Infection and Immunity, University College London, London, UK.
- San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Hospital, Milan, Italy.
- Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
- NIHR Great Ormond Street Hospital Biomedical Research Centre, 30 Guilford Street, London WC1N 1EH, UK.
Förderung
- UKRI Medical Research Council
- Ministero dell'Istruzione dell'Università e della Ricerca
- Great Ormond Street Hospital Children's Charity
- Great Ormond Street Hospital for Children
- Wellcome Trust
- Jeffrey Modell Foundation
Zitieren
APA
Naseem, A., Vetharoy, W., Whittaker, T. E., Zinghirino, F., Carusillo, A., Ghosh, R., Gomez-Castaneda, E., Ali, H., Cipriani, C., Montini, E., Thrasher, A. J., Santilli, G., Cesana, D., Turchiano, G., & Cavazza, A. (2026). In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing. Molecular Therapy Advances, 34(3), 201816. https://doi.org/10.1016/j.omta.2026.201816
Vancouver
Naseem A, Vetharoy W, Whittaker TE, Zinghirino F, Carusillo A, Ghosh R, et al. In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing. Molecular Therapy Advances. 2026;34(3):201816. doi:10.1016/j.omta.2026.201816
BibTeX
@article{Naseem2026,
author = {Naseem, Asma and Vetharoy, Winston and Whittaker, Thomas E and Zinghirino, Federica and Carusillo, Antonio and Ghosh, Roopkatha and Gomez-Castaneda, Eduardo and Ali, Hashim and Cipriani, Carlo and Montini, Eugenio and Thrasher, Adrian J and Santilli, Giorgia and Cesana, Daniela and Turchiano, Giandomenico and Cavazza, Alessia},
title = {In-depth characterization of stem cell potency and genotoxicity for clinical-scale ex vivo CRISPR-Cas9 gene editing},
journal = {Molecular Therapy Advances},
year = {2026},
volume = {34},
number = {3},
pages = {201816},
doi = {10.1016/j.omta.2026.201816}
}
EUVIMED